Amendments to the Claims:

Claims 35-59 are pending and presented for examination. Claims 1-34 are canceled without prejudice or disclaimer. Claims 35-59 are newly added.

Listing of Claims:

1.-34. (Canceled)

35. (New) A compound having the formula:



and pharmaceutically acceptable salts thereof;

wherein R^{18} is selected from the group consisting of $(C_1\text{-}C_4)$alkyl, $(C_1\text{-}C_4)$alkoxy, $(C_1\text{-}C_4)$heteroalkyl, $(C_1\text{-}C_4)$haloalkyl, $(C_1\text{-}C_4)$haloalkoxy and halogen;

B is a phenyl group optionally substituted with one to three substituents selected from the group consisting of halogen, $(C_1\text{-}C_4)$haloalkyl, $(C_1\text{-}C_4)$haloalkoxy, $(C_1\text{-}C_4)$alkyl, $(C_1\text{-}C_4)$alkoxy, $(C_1\text{-}C_4)$heteroalkyl, phenyl, phenoxy and $-CO_2Me$;

R^{16} and R^{17} are independently selected from the group consisting of hydrogen, $(C_1\text{-}C_8)$alkyl and $(C_1\text{-}C_8)$heteroalkyl; or R^{16} and R^{17} together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocyclic ring optionally having additional heteroatoms as ring members and optionally substituted with substituents selected from the group consisting of $(C_1\text{-}C_8)$alkyl, $(C_1\text{-}C_8)$heteroalkyl, hydroxyl, amino, acetoamido and phenyl.

36. (New) A compound of claim **35** wherein R^{18} is $(C_1\text{-}C_4)$haloalkyl.

37. (New) A compound of claim **35** wherein $-NR^{16}R^{17}$ is selected from the group consisting of:



38 (New) A compound of claim **35** wherein B is a phenyl group optionally having one to three substituents selected from the group consisting of halogen, (C_1-C_4)haloalkyl, (C_1-C_4)alkyl, (C_1-C_4)alkoxy and -CO_2Me.

39. (New) A compound of claim **38** wherein B is a phenyl group having one to three substituents selected from the group consisting of -CO_2Me, trifluoromethyl, fluoro, chloro, and methoxy.

40. (New) A compound of claim **35** having the formula:



wherein B is a phenyl group optionally substituted with one to three substituents selected from the group consisting of halogen, (C_1-C_4)haloalkyl, (C_1-C_4)haloalkoxy, (C_1-C_4)alkyl, (C_1-C_4)alkoxy, (C_1-C_4)heteroalkyl, phenyl, phenoxy and -CO_2Me;

R^{16} and R^{17} are independently selected from the group consisting of hydrogen, (C_1-C_8)alkyl and (C_1-C_8)heteroalkyl; or R^{16} and R^{17} together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocyclic ring optionally having additional heteroatoms as ring members and optionally substituted with substituents selected from the group consisting of (C_1-C_8)alkyl, (C_1-C_8)heteroalkyl, hydroxyl, amino, acetoamido and phenyl.

41. (New) A compound of claim **40** wherein -$NR^{16}R^{17}$ is selected from the group consisting of:



42. (New) A compound of claim **40** selected from the group consisting of:




and


43. (New) A method of reducing bacterial growth on a surface, said method comprising contacting said surface with a compound of claim **35**.

44. (New) A method of treating a bacterial infection comprising contacting a subject in need of such treatment with an effective amount of a compound having the formula:



and pharmaceutically acceptable salts thereof;

wherein R^{18} is selected from the group consisting of (C_1-C_4)alkyl, (C_1-C_4)alkoxy, (C_1-C_4)heteroalkyl, (C_1-C_4)haloalkyl, (C_1-C_4)haloalkoxy and halogen;

B is a phenyl group optionally substituted with one to three substituents selected from the group consisting of halogen, (C_1-C_4)haloalkyl, (C_1-C_4)haloalkoxy, (C_1-C_4)alkyl, (C_1-C_4)alkoxy, (C_1-C_4)heteroalkyl, phenyl, phenoxy and -CO_2Me;

R^{16} and R^{17} are independently selected from the group consisting of hydrogen, (C_1-C_8)alkyl and (C_1-C_8)heteroalkyl; or R^{16} and R^{17} together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocyclic ring optionally having additional

heteroatoms as ring members and optionally substituted with substituents selected from the group consisting of (C_1-C_8)alkyl, (C_1-C_8)heteroalkyl, hydroxyl, amino, acetoamido and phenyl.

45. (New) A method in accordance with claim **44** wherein R^{18} is (C_1-C_4)haloalkyl.

46. (New) A method in accordance with claim **44** wherein $-NR^{16}R^{17}$ is selected from the group consisting of:



47. (New) A method in accordance with claim **44** wherein B is a phenyl group optionally having one to three substituents selected from the group consisting of halogen, (C_1-C_4)haloalkyl, (C_1-C_4)alkyl, (C_1-C_4)alkoxy and $-CO_2Me$.

48. (New) A method in accordance with claim **47** wherein B is a phenyl group having one to three substituents selected from the group consisting of -CO_2Me, trifluoromethyl, fluoro, chloro, and methoxy.

49. (New) A method in accordance with claim **44** having the formula:



wherein B is a phenyl group optionally substituted with one to three substituents selected from the group consisting of halogen, (C_1-C_4)haloalkyl, (C_1-C_4)haloalkoxy, (C_1-C_4)alkyl, (C_1-C_4)alkoxy, (C_1-C_4)heteroalkyl, phenyl, phenoxy and -CO_2Me;

R^{16} and R^{17} are independently selected from the group consisting of hydrogen, (C_1-C_8)alkyl and (C_1-C_8)heteroalkyl; or R^{16} and R^{17} together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocyclic ring optionally having additional heteroatoms as ring members and optionally substituted with substituents selected from the group consisting of (C_1-C_8)alkyl, (C_1-C_8)heteroalkyl, hydroxyl, amino, acetoamido and phenyl.

50. (New) A method in accordance with claim **49** wherein -$NR^{16}R^{17}$ is selected from the group consisting of:



51. (New) A method in accordance with claim **49**, wherein said compound is selected from the group consisting of:



52. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound having the formula:



and pharmaceutically acceptable salts thereof;

wherein R^{18} is selected from the group consisting of $(C_1\text{-}C_4)$alkyl, $(C_1\text{-}C_4)$alkoxy, $(C_1\text{-}C_4)$heteroalkyl, $(C_1\text{-}C_4)$haloalkyl, $(C_1\text{-}C_4)$haloalkoxy and halogen;

B is a phenyl group optionally substituted with one to three substituents selected from the group consisting of halogen, $(C_1\text{-}C_4)$haloalkyl, $(C_1\text{-}C_4)$haloalkoxy, $(C_1\text{-}C_4)$alkyl, $(C_1\text{-}C_4)$alkoxy, $(C_1\text{-}C_4)$heteroalkyl, phenyl, phenoxy and $-CO_2Me$;

R^{16} and R^{17} are independently selected from the group consisting of hydrogen, $(C_1\text{-}C_8)$alkyl and $(C_1\text{-}C_8)$heteroalkyl; or R^{16} and R^{17} together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocyclic ring optionally having additional heteroatoms as ring members and optionally substituted with substituents selected from the group consisting of $(C_1\text{-}C_8)$alkyl, $(C_1\text{-}C_8)$heteroalkyl, hydroxyl, amino, acetoamido and phenyl.

53. (New) A composition of claim **52** wherein R^{18} is $(C_1\text{-}C_4)$haloalkyl.

54. (New) A composition of claim **52** wherein $-NR^{16}R^{17}$ is selected from the group consisting of:



55. (New) A composition of claim **52** wherein B is a phenyl group optionally having one to three substituents selected from the group consisting of halogen, $(C_1\text{-}C_4)$haloalkyl, $(C_1\text{-}C_4)$alkyl, $(C_1\text{-}C_4)$alkoxy and $\text{-}CO_2Me$.

56. (New) A composition of claim **55** wherein B is a phenyl group having one to three substituents selected from the group consisting of $\text{-}CO_2Me$, trifluoromethyl, fluoro, chloro, and methoxy.

57. (New) A composition of claim **52** having the formula:



wherein B is a phenyl group optionally substituted with one to three substituents selected from the group consisting of halogen, $(C_1\text{-}C_4)$haloalkyl, $(C_1\text{-}C_4)$haloalkoxy, $(C_1\text{-}C_4)$alkyl, $(C_1\text{-}C_4)$alkoxy, $(C_1\text{-}C_4)$heteroalkyl, phenyl, phenoxy and $-CO_2Me$;

R^{16} and R^{17} are independently selected from the group consisting of hydrogen, $(C_1\text{-}C_8)$alkyl and $(C_1\text{-}C_8)$heteroalkyl; or R^{16} and R^{17} together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocyclic ring optionally having additional heteroatoms as ring members and optionally substituted with substituents selected from the group consisting of $(C_1\text{-}C_8)$alkyl, $(C_1\text{-}C_8)$heteroalkyl, hydroxyl, amino, acetoamido and phenyl.

58. (New) A composition of claim **57** wherein $-NR^{16}R^{17}$ is selected from the group consisting of:



59. (New) A composition of claim **57** comprising a compound selected from the group consisting of:







and



3